LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | Linifanib | 1.11 | uM | LJP6 | 2 | J09 | 72 | hr | 1657 | 5758 | 5505 | 1.0458 | 1.0656 |
| BT-20 | Linifanib | 1.11 | uM | LJP6 | 3 | J09 | 72 | hr | 1657 | 5764 | 5505 | 1.0469 | 1.0671 |
| BT-20 | Linsitinib | 1.11 | uM | LJP5 | 1 | O21 | 72 | hr | 1657 | 4968 | 5505 | 0.9023 | 0.8603 |
| BT-20 | Linsitinib | 1.11 | uM | LJP5 | 2 | O21 | 72 | hr | 1657 | 5101 | 5505 | 0.9265 | 0.8948 |
| BT-20 | Linsitinib | 1.11 | uM | LJP5 | 3 | O21 | 72 | hr | 1657 | 4798 | 5505 | 0.8715 | 0.8161 |
| BT-20 | Mitoxantrone | 1.11 | uM | LJP5 | 1 | C21 | 72 | hr | 1657 | 1456 | 5505 | 0.2645 | -0.0524 |
| BT-20 | Mitoxantrone | 1.11 | uM | LJP5 | 2 | C21 | 72 | hr | 1657 | 1398 | 5505 | 0.2539 | -0.0675 |
| BT-20 | Mitoxantrone | 1.11 | uM | LJP5 | 3 | C21 | 72 | hr | 1657 | 1627 | 5505 | 0.2955 | -0.0080 |
| BT-20 | Mitoxantrone | 1.11 | uM | LJP6 | 1 | C21 | 72 | hr | 1657 | 1370 | 5505 | 0.2488 | -0.0748 |
| BT-20 | Mitoxantrone | 1.11 | uM | LJP6 | 2 | C21 | 72 | hr | 1657 | 1493 | 5505 | 0.2712 | -0.0428 |
| BT-20 | Mitoxantrone | 1.11 | uM | LJP6 | 3 | C21 | 72 | hr | 1657 | 1550 | 5505 | 0.2815 | -0.0280 |
| BT-20 | MK2206 | 1.11 | uM | LJP6 | 1 | F03 | 72 | hr | 1657 | 3468 | 5505 | 0.6299 | 0.4705 |
| BT-20 | MK2206 | 1.11 | uM | LJP6 | 2 | F03 | 72 | hr | 1657 | 3650 | 5505 | 0.6630 | 0.5178 |
| BT-20 | MK2206 | 1.11 | uM | LJP6 | 3 | F03 | 72 | hr | 1657 | 3498 | 5505 | 0.6354 | 0.4783 |
| BT-20 | Neratinib | 1.11 | uM | LJP5 | 1 | A15 | 72 | hr | 1657 | 3874 | 5505 | 0.7036 | 0.5760 |
| BT-20 | Neratinib | 1.11 | uM | LJP5 | 2 | A15 | 72 | hr | 1657 | 3988 | 5505 | 0.7243 | 0.6056 |
| BT-20 | Neratinib | 1.11 | uM | LJP5 | 3 | A15 | 72 | hr | 1657 | 3521 | 5505 | 0.6395 | 0.4842 |
| BT-20 | Nilotinib | 1.11 | uM | LJP5 | 1 | N15 | 72 | hr | 1657 | 5255 | 5505 | 0.9545 | 0.9349 |
| BT-20 | Nilotinib | 1.11 | uM | LJP5 | 2 | N15 | 72 | hr | 1657 | 5514 | 5505 | 1.0015 | 1.0022 |
| BT-20 | Nilotinib | 1.11 | uM | LJP5 | 3 | N15 | 72 | hr | 1657 | 5237 | 5505 | 0.9512 | 0.9302 |
| BT-20 | Nintedanib | 1.11 | uM | LJP6 | 1 | H03 | 72 | hr | 1657 | 4669 | 5505 | 0.8480 | 0.7826 |
| BT-20 | Nintedanib | 1.11 | uM | LJP6 | 2 | H03 | 72 | hr | 1657 | 5097 | 5505 | 0.9258 | 0.8938 |
| BT-20 | Nintedanib | 1.11 | uM | LJP6 | 3 | H03 | 72 | hr | 1657 | 4664 | 5505 | 0.8471 | 0.7813 |
| BT-20 | NU7441 | 1.11 | uM | LJP5 | 1 | C09 | 72 | hr | 1657 | 5973 | 5505 | 1.0849 | 1.1215 |
| BT-20 | NU7441 | 1.11 | uM | LJP5 | 2 | C09 | 72 | hr | 1657 | 5268 | 5505 | 0.9568 | 0.9382 |